Australian Injecting and Illicit Drug Users League. Policy Position Paper 8 Retractable Syringes

Similar documents
IMPORTANCE OF PEER-BASED SERVICES & NEEDLE & SYRINGE PROGRAMS (NSP)

Needle and Syringe Programs - 17 October 2013

Eliminating Viral Hepatitis in Australia: Where are we in 2017?

The Silent Disease Inquiry into Hepatitis C in Australia

Dr Angella Duvnjak. CEO, Australian Injecting and Illicit Drug Users League. Dr Angella Duvnjak Viral Hepatitis Conference

Re Joint Committee on Law Enforcement Inquiry into crystal methamphetamine (ice)

Single-Use Safety Syringes

Leading Australia towards the elimination of viral hepatitis

Legislative and Policy Barriers to Needle & Syringe Programs and Injecting Equipment Access for People Who Inject Drugs

The new WHO global injection safety policy and campaign

Michael Levy Australian National University

State and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005

Infectious Disease The Public Health Response

Syringe Exchange Programs December 2005

Victorian AIDS Council Gay Men s Health Centre

Substance use and misuse

Consultation on the Draft National Strategies for Blood Borne Viruses and Sexually Transmissible Infections

Low dead space. injecting equipment. from exchangesupplies.org

Guidelines For Services Providing Injecting Equipment

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

CAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA?

>Hepatitis NSW will continue to

Summary Report. Evaluation of Retractable Syringes in a Measles-Rubella Immunization Campaign in Peru. October 2008

MOVEMBER FUNDED MEN S HEALTH INFORMATION RESOURCES EVALUATION BRIEF. 1 P age

Carers Australia Strategic Plan

Regional Program Harm Reduction Works Fund It! Baseline assessment. Country: Georgia. Preliminary analysis. 10 October 2014

Needle and syringe distribution

Hepatitis C Strategy. About us. What is hepatitis C?

UNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,

Taking away the chaos The health needs of people who inject drugs in public places in Glasgow city centre

Prison needle exchange: Review of the evidence

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014

Overview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition

POLICY POSITION. Access to Hepatitis C Treatments

Technical Guidance Note for Global Fund HIV Proposals

Occupational Hazard: A Report on Needle-Stick Injuries in Arusha, Tanzania By Reem Mahmood

Advocating for Sensible Policies in the Age of HCV Cure

Integrating hepatitis C treatment in a regional setting The Cairns Experience. DANA 2018 Morag Goodinson

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

Plain packaging of tobacco: Evidence and policy. ISM Institute for Social Marketing

Transmission/Prevention

MINISTRY OF HEALTH STRATEGIC FRAMEWORK OF COMMUNICATION FOR HIV/AIDS AND STIs INTRODUCTION

DRUG DIVERSION STUDY TOUR ANNIE MADDEN EXECUTIVE OFFICER AUSTRALIAN INJECTING AND ILLICIT DRUG USERS LEAGUE (AIVL)

HIV VACCINE TRIALS: LEGAL AND ETHICAL ISSUES, SOCIAL CONSEQUENCES

Acknowledgement goes to WHO for use of their hand washing technique

Operational Guideline

TREATMENT OF RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (ATAHC II)

Drug Use, Harm Reduction, and HIP

Government of Canada Federal AIDS Initiative Milestones

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

FPA Sri Lanka Policy: Men and Sexual and Reproductive Health

Minister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018

REDUCING THE HARM OF INJECTION DRUG USE

Promoting hepatitis B vaccination

IMPLEMENTING HIV PREVENTION AMONGST YOUNG PEOPLE IN A GEOGRAPHIC FOCUSED APPROACH IN SOUTH AFRICA

Needle Exchange Programs

Best Prac*ces Model for Harm Reduc*on in Bri*sh Columbia: Community Involvement

ESTABLISHMENT OF SUPERVISED INJECTING FACILITY IN VICTORIA SUBMITTED BY THE SALVATION ARMY

What is harm reduction?

IMPLICATIONS OF THE EUROPEAN COUNCIL DIRECTIVE 2010/32/EU ON PHARMACY ASEPTIC PRACTICES IN THE UK

2020 Vision: making England s HIV prevention response the best in the world

At the dark end of the street A report on street based injecting in Dublin City Centre

Harm Reduction in Nigeria

Script for Podcast on Injection Safety

The information provided should be used as a guide only and is not a substitute for medical advice.

Statement about the release of the National Ice Taskforce Report, release of two Review report and various announcements by the Australian Government

Medical Director. and in prison settings in Romania. Ministry of Justice National Administration of Penitentiaries L IŢ

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

How to Use ENBREL : Vial Adapter Method

1. How Does Local Government Affect the Homeless

Scottish Health Action on Alcohol Problems. Alcohol (Licensing, Public health and Criminal Justice) (Scotland) Bill

Provincial Infectious Diseases Advisory Committee Public Health Response to Hepatitis C

CIMZIA (certolizumab pegol)

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

who use drugs in order to assist them in reducing harm while in the cycle of addiction

Advocating for Syringe Exchange Programs

WHAT WORKS? A comprehensive guide to safer needle and syringe selection for injecting drug users. Second edition. Fully revised and updated

Assessment of HIV Knowledge, Attitude and Behaviour among Hepatitis C-Infected Patients Who Inject Drugs in Tbilisi, Georgia

Part 1: Introduction & Overview

REDUCING THE HARM OF INJECTION DRUG USE

A Survey of Health and Wellbeing in the Creative Sector

Maximising the effectiveness of needle exchange. with low dead space syringes and prevention of accidental sharing

HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report

Continued in Part II (additional reading list at end of Part II)

Improving NSP and Harm Reduction Services. Jason Farrell, European HCV and Drug Use Initiative

Package Leaflet: Information for the User

Building a New Approach to Health Care Services for Hard to Reach Clients

Introduction Define sexual health brainstorm STI symptoms group work (quiz) Time Activity Resource 5 min Introduction

NEEDLESTICK PREVENTION

Version for the Silent Procedure 29 April Agenda item January Hepatitis

New WHO global injection safety initiative

Addressing Drug Addiction in Australia

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

Submission to the Tasmanian Government. A Healthy Tasmania Five Year Strategic Plan Community Consultation Draft

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

MAKE SMART INJECTION CHOICES INJECTION PROVIDERS GUIDE FOR SAFE INJECTIONS

NEEDLE & SYRINGE PROGRAMS IN PRISONS AN INTERNATIONAL REVIEW MAY 2015

19/08/2014. What is Injection Safety?

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Transcription:

Australian Injecting and Illicit Drug Users League Policy Position Paper 8 Retractable Syringes June 2003

Discussion A retractable device is a combination needle and syringe where the needle goes back inside the barrel or retracts when the plunger is fully pushed down the end of the barrel. There are generally two ways for the needle to be retracted: Automatically: when the plunger reaches a certain point as it is being pushed down, the needle is automatically activated to retract; Manually: when the person is finished injecting they push a small button on the top of the plunger or press the plunger down hard to the end of the barrel which retracts the needle. Retractable needles and syringes are not a new issue for Australia and have been publicly discussed since Needle and Syringe Programs (NSPs) have been in existence in Australia. The issue has been thoroughly investigated a number of times but because retractable have always been shown to have many negative and unacceptable health consequences for drug users, they have always been disregarded as a viable option. However, there is renewed interest in this technology among some parliamentarians coupled with pressure from the community on the disposal of injecting equipment and the vigorous lobbying by some of the manufacturers of retractable needles and syringes. This renewed interest resulted in the Federal Government announcing in the 2002/03 Federal Budget that, The Government will provide $27.5 million to fund a product development and implementation strategy for the introduction of retractable needle and syringe technology into Australia. Retractable needle and syringe technology will assist in reducing the risk of acquiring blood borne viruses from needle stick injuries. 1 This funding was appropriated over a four year period. Significant advocacy and lobbying was undertaken by AIVL and other stakeholders in response to this allocation of funding. Subsequently, the Federal Budget 2003/04 adjusted this funding allocation by: redirecting funding of $8.7 million over 2003-04 and 2004-05 from the introduction of retractable needle and syringe technology to other Health and Ageing portfolio initiatives in this package which seeks to reduce the demand for illicit drugs. The budget stated that this was because: The original level of research and development funding for retractable needle and syringe technology is no longer required because there has been a significant increase in the number of commercial providers developing this technology. The Government will continue to provide $17.5 million over three years ($2.8 million in 2003-04, $2.6 million in 2004-05 and $12.1 million in 2005-06) to address community concerns about the risk of injury from needles discarded in public places through funding for the final phase of research and development, including pilots of the technology in selected settings and the 1 Federal Budget 2002/03 Department of Health and Ageing 2

implementation of retractable technology across needle and syringe programs nationally. Such financial and political backing combined has made it so that retractable needles and syringes are now a real possibility in the Australian context. Retractable needles and syringes are largely a response to the perceived rather than actual problem in the community of the risk of blood borne virus (BBV) transmission risk from publicly discarded needles and syringes. While it is difficult to ascertain exact figures regarding the numbers of publicly discarded equipment around Australia, some estimates can be made from figures obtained through safe disposal hotlines and other mechanisms. From these sources it is estimated that less than one percent of equipment is being inappropriately discarded. Recent research undertaken by AIVL through the National Injecting Equipment Disposal Study 2002 showed that injecting drug users (IDU) are engaged in a range of different strategies to dispose of used injecting equipment and take this issue very seriously. It also highlighted that users often felt anxious about public discarding of used injecting equipment and felt forced into such behaviour when there were no other options. The most common reason cited for this was the fear of being arrested when carrying used equipment. Stigma and discrimination associated with injecting drug use and a general fear of contagion, have led to a highly emotional response by some members of the community to publicly discarded injecting equipment. An empty swab packet or a water vial can bring on the same emotional response from some members of the community as an actual discarded needle and syringe. AIVL believes the current interest in the introduction of retractable needle and syringes in the IDU context is largely based on the erroneous belief that the general public is at high risk of contracting a blood borne virus (BBV) due to a needlestick from a discarded needle and syringe. In reality however, there is currently no documented cases of BBV transmission from a publicly discarded needles and syringe. In this way, retractable needles and syringes are attempting to fix a non-existent problem. Rather than leading to increased community safety in relation to BBVs, AIVL is concerned that retractable needles and syringes could lead to higher levels of BBV transmission due to the devices being unacceptable to injecting drug users. We are very concerned that design problems could result in people stockpiling and reusing the current non-retractable needles and syringes and/or having to inject others more often as people struggle to use the new technology. The cost of illicit drugs and dependency issues are likely to mean that people will be unwilling to use an unknown device if they think there is a chance of losing all or part of their shot or sustaining vein damage during retraction. In this context, most injecting drug users are reluctant to use a different brand of the same basic 1ml needle and syringe let alone shifting to an entirely new technology in the form of retractable needles and syringes. In summary, AIVL believes parliamentarians, policy makers and community leaders must take responsibility for the current concerns in the community as they have neither ensured that drug users can easily and safely dispose of used injecting equipment or ensured that the public is properly informed on the actual levels of public disposal or the low risk levels for contracting BBVs from publicly discarded equipment. Retractable 3

syringe technology is now moving forward and is of great concern to AIVL, its member organizations and the people these organizations represent. Position Retractable syringes will be an expensive option to both implement and purchase. AIVL is concerned that retractable syringes could turn NSPs that are extremely effective both in terms of cost and disease prevention into expensive and inefficient programs. AIVL is concerned about the potential for retractable syringes to be re-used and be not fully functional. This means that while the unit can be re-used it is less likely for it to be able to be cleaned sufficiently and will place users at great risk of BBVs. This in turn may lead to an increase in the likelihood in sharing of equipment by individuals who will be reluctant to let the device retract for fear of not being able to re-use it. Retractable syringes may increase the need for users to inject each other and this may increase the chance for the transmission of BBVs. This is because individuals may struggle to learn and manage the retractable mechanism. This has the potential for undoing over ten years of harm reduction work and peer education. Retractable syringes are unlikely to be accepted by injecting drug users who will not accept inferior or ineffective equipment. If as AIVL predicts that large numbers of individuals will reject this technology then the potential for the reusing of equipment will greatly increase. This will result in increased health issues for individuals such as hepatitis C and HIV transmission, vein care problems, abscesses and other bacterial infections. Retractable syringes have the potential to cause an emergence of a black market in the currently available injecting equipment. Black markets in both new and used equipment have occurred in countries where access to injecting equipment is limited or does not exist and is also the case in Australian prisons. Drug users are already forced to interact with the black market to access currently illicit drugs and should not be forced to do so to protect their health. Retractable syringes will not reduce community concern in relation to publicly discarded injecting equipment. This is because such concern is related to perception rather than reality. Negative community attitudes to IDU and the fear of BBVs means that there mere sight of injecting paraphernalia creates major concern. The fact that there has never been a documented case of HIV or hepatitis C infection from publicly discarded injecting equipment seems to be irrelevant. Responses seem to focus instead on perpetuating stigma, fear and discrimination. Retractable syringes may in fact lead to more publicly discarded injecting equipment as IDUs may see them as safe to leave where they inject. This in itself will cause an even greater negative community response and will undo many years of work in relation to the disposal of used injecting equipment. 4

Recommendations That the Australian Government review funding of the retractable needles and syringes initiative and redirect it to: o Expand current NSPs; o Preventing the further transmission of hepatitis C and HIV among people who inject drugs; o Expand and increase the availability of safe disposal options for people who inject drugs; o Educate the public on the reality of the possibility for BBV transmission from publicly disposed injecting equipment alongside a campaign to educate the public on what to do should they find publicly disposed injecting equipment. That the Australian Government leads and assists the state and territory jurisdictions to: o Repeal the current laws that deter people who inject drugs from carrying and disposing of used injecting equipment such as self administration laws and safe disposal laws (in Qld only); o Create consistent national guidelines and legislation on the disposal of injecting equipment. That the states and territories undertake to positively advertise to general community the benefits of NSPs with the aim of increasing community understanding and support of this important public health initiative. That peer education is recognised as the primary vehicle by which to educate drug users on safe disposal and that drug user organisations be funded at the national and state and territory levels to carry out these roles. That constructive dialogue and education be initiated to engage the media to report appropriately on the issue of public disposal of injecting equipment and NSPs more generally. Should negative media occur that all Governments and other stakeholders respond factually and challenge sensationalist and inaccurate media reporting. 5

6